摘要
目的比较食管癌单纯后程加速超分割放射治疗(LCAHR)与LCAHR联合化学治疗(LCAHR+C)的疗效。方法将78例食管鳞癌随机分成LCAHR组(单放组)和LCAHR联合顺铂(DDP)+5-氟尿嘧啶(5-Fu)化疗组(联合组)各39例。单放组前2/3疗程为常规分割,36~40Gy后改加速超分割(1.5Gy/次,2次d),照射27Gy;联合组加用DDP25mgm2、5-Fu500mgm2化疗,共3~4个周期。结果单放组及联合组的1、2、3年生存率分别为71.79%、43.59%、30.77%和87.18%、69.23%、51.28%,两组差别有显著性意义(P<0.05);1、2、3年局控率分别为71.79%、48.72%、35.90%和87.18%、71.43%、58.70%,两组差别有显著性意义(P<0.05)。联合组急性放射性反应如放射性食管、气管炎,以及血液、消化系统反应发生率均高于单放组,但患者尚能耐受。结论食管癌LCAHR联合DF方案化疗结果优于单纯LCAHR。
Objective To compare the therapeutic efficacy and toxicity of late course accelerated hyper-fractionation radiotherapy (LCAHR) and LCAHR combined with chemotherapy(LCAHR+C) on carcinoma of esophagus. Methods Seventy cases of esophageal carcinoma were randomly divided into two groups patients in LCAHR group were treated with late course accelerated hyper-fractionation radiotherapy (LCAHR) alone, and patients in group LCAHR+C were treated with combination of LCAHR and concurrent chemotherapy(LCAHR+C). All patients were given with 6MV X-ray. During the first two-thirds of the course patients were given with conventional fractionation regimen the total dose was 36 Gy~40 Gy/18F~20Fand the followed by LCAHR,1.5 Gy per fraction twice daily with the total dose of 63~67Gy/40F/40~42d. The LCAHR + C group also received DF regimen (DDP 25mg/m2+5-Fu 500 mg/m2)at the beginning of LCAHR with total of 3~4 cycles. Results The 1, 2 and 3 year survival rate in LCAHR group and LCAHR+C group were 71.79%,43.59%,30.77% and 87.18%,69.23%,51.28% respectively( χ2=4.20,P<0.05), The 1,2 and 3 year local control rate in LCAHR group and LCAHR+C group were 71.79%,48.72%,35.90% and 87.18%,71.43% ,58.70% (χ2=4.154,P<0.05).The acute toxic effect was severer in the LCAHR +C group than that in the LCAHR group,but all patients could tolerate. Conclusion The therapeutic efficacy of LCAHR +C on carcinoma of esophagus is superior to that of LCAHR. [
出处
《浙江医学》
CAS
2005年第6期412-414,共3页
Zhejiang Medical Journal
关键词
食管癌
加速超分割
放疗
化疗
LCAHR
] esophageal neoplasms late course accelerated hyper-fractionation radiotherapy chemoth- erapy prognosis